Homburger on ADC Therapeutics’ USD 105m offering
Homburger advised ADC Therapeutics, a commercial-stage biotechnology company producing antibody drug conjugates (ADCs) for cancer patients, on its 13.4 m of common shares, and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8.1 m common shares, raising aggregate gross proceeds of USD 105 m.
Homburger’s team
Homburger advised ADC Therapeutics on Swiss law and tax aspects of this transaction, operating with a team led by Daniel Häusermann (pictured) and which further comprised Estelle Piccard and Bianca Nedwed (both capital markets, corporate / M&A) as well as Stefan Oesterhelt and Philippe Weber (both tax).
